Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

White House Coverage

FDA Commissioner Marty Makary (L) and Secretary of Health and Human Services Robert F. Kennedy Jr (R) listen as Medicare and Medicaid Administrator Mehmet Oz speaks during a press briefing at the White House, Washington, DC, USA, 07 January 2026. The US government have released updated dietary guidelines for Americans. EPA/WILL OLIVER/POOL

E

White House Coverage

FDA Commissioner Marty Makary alongside, Medicare and Medicaid Administrator Mehmet Oz (L), Secretary of Health and Human Services Robert F. Kennedy Jr (C-R) Secretary of Agriculture Brooke Rollins (R) during a press briefing at the White House, Washington, DC, USA, 07 January 2026. The US government have released updated dietary guidelines for Americans. EPA/WILL OLIVER/POOL

E

White House Coverage

Secretary of Health and Human Services Robert F. Kennedy Jr speaks alongside Dr. Ben Carson, (L) FDA Commissioner Marty Makary (2-L), Medicare and Medicaid Administrator Mehmet Oz (C-R), Secretary of Agriculture Brooke Rollins (2-R) White House Press Secretary Karoline Leavitt (R) during a press briefing at the White House, Washington, DC, USA, 07 January 2026. The US government have released updated dietary guidelines for Americans. EPA/WILL OLIVER/POOL

E

White House Coverage

Secretary of Agriculture Brooke Rollins speaks alongside FDA Commissioner Marty Makary (L) and Secretary of Health and Human Services Robert F. Kennedy Jr (R) during a press briefing at the White House, Washington, DC, USA, 07 January 2026. The US government have released updated dietary guidelines for Americans. EPA/WILL OLIVER/POOL

E

White House Coverage

FDA Commissioner Marty Makary speaks alongside, Medicare and Medicaid Administrator Mehmet Oz (L), Secretary of Health and Human Services Robert F. Kennedy Jr (C-R) Secretary of Agriculture Brooke Rollins (R) during a press briefing at the White House, Washington, DC, USA, 07 January 2026. The US government have released updated dietary guidelines for Americans. EPA/WILL OLIVER/POOL

E

White House Coverage

Secretary of Health and Human Services Robert F. Kennedy Jr speaks alongside FDA Commissioner Marty Makary (L), Medicare and Medicaid Administrator Mehmet Oz (C-R), Secretary of Agriculture Brooke Rollins (R) during a press briefing at the White House, Washington, DC, USA, 07 January 2026. The US government have released updated dietary guidelines for Americans. EPA/WILL OLIVER/POOL

E

Trump Marijuana Executive Order Signing

Martin A Makary, Commissioner, US Food and Drug Administration (FDA), looks on as United States President Donald J Trump signs an executive order to “reschedule marijuana from a schedule one to a schedule three controlled substance with legitimate medical uses” in the Oval Office of the White House in Washington, DC, USA, on Thursday, December 18, 2025. Credit: Aaron Schwartz / Pool via CNP

E

Donald Trump Announces Drug Pricing Deal With Pharma Giants - DC

Robert F. Kennedy Jr., US secretary of Health and Human Services (HHS), left, and Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Photo by Aaron Schwartz/Pool/ABACAPRESS.COM

E

Donald Trump Announces Drug Pricing Deal With Pharma Giants - DC

Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Photo by Aaron Schwartz/Pool/ABACAPRESS.COM

E

Donald Trump Announces Drug Pricing Deal With Pharma Giants - DC

Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, from left, David Ricks, chief executive officer of Eli Lilly & Co., and Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Photo by Aaron Schwartz/Pool/ABACAPRESS.COM

E

Trump Speaks in The Oval Office - Washington

Martin Makary, commissioner of the Food and Drug Administration (FDA), in the Oval Office of the White House in Washington, DC, US, on Thursday, Nov. 6, 2025. Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Photo by Aaron Schwartz/Pool/ABACAPRESS.COM

E

Trump Signs an Executive Order Lowering Prescription Drug Costs

Martin A Makary, Commissioner, US Food and Drug Administration (FDA) makes remarks following US President Donald J Trump’s remarks on the India-Pakistan cease-fire, the new US-China Trade Deal, the return of Eden Alexander from Hamas captivity and the high cost of prescription drugs before signing an executive order that he promises will lower the cost of those prescription drugs almost immediately, during a press conference in the Roosevelt Room of the White House in Washington, DC, US, on Monday, May 12, 2025. Photo by Chris Kleponis/Pool/ABACAPRESS.COM

E

Trump Signs an Executive Order Lowering Prescription Drug Costs

Martin A Makary, Commissioner, US Food and Drug Administration (FDA) makes remarks following US President Donald J Trump’s remarks on the India-Pakistan cease-fire, the new US-China Trade Deal, the return of Eden Alexander from Hamas captivity and the high cost of prescription drugs before signing an executive order that he promises will lower the cost of those prescription drugs almost immediately, during a press conference in the Roosevelt Room of the White House in Washington, DC, US, on Monday, May 12, 2025. Photo by Chris Kleponis/Pool/ABACAPRESS.COM

E

Trump Signs an Executive Order Lowering Prescription Drug Costs

Martin A Makary, Commissioner, US Food and Drug Administration (FDA) makes remarks following US President Donald J Trump’s remarks on the India-Pakistan cease-fire, the new US-China Trade Deal, the return of Eden Alexander from Hamas captivity and the high cost of prescription drugs before signing an executive order that he promises will lower the cost of those prescription drugs almost immediately, during a press conference in the Roosevelt Room of the White House in Washington, DC, US, on Monday, May 12, 2025. Photo by Chris Kleponis/Pool/ABACAPRESS.COM

E

Trump Signs an Executive Order Lowering Prescription Drug Costs

Martin A Makary, Commissioner, US Food and Drug Administration (FDA) makes remarks following US President Donald J Trump’s remarks on the India-Pakistan cease-fire, the new US-China Trade Deal, the return of Eden Alexander from Hamas captivity and the high cost of prescription drugs before signing an executive order that he promises will lower the cost of those prescription drugs almost immediately, during a press conference in the Roosevelt Room of the White House in Washington, DC, US, on Monday, May 12, 2025. Photo by Chris Kleponis/Pool/ABACAPRESS.COM

E

Trump Signs an Executive Order Lowering Prescription Drug Costs

Martin A Makary, Commissioner, US Food and Drug Administration (FDA) listens to United States President Donald J Trump’s remarks on the India-Pakistan cease-fire, the new US-China Trade Deal, the return of Eden Alexander from Hamas captivity and the high cost of prescription drugs before signing an executive order that he promises will lower the cost of those prescription drugs almost immediately, during a press conference in the Roosevelt Room of the White House in Washington, DC, US, on Monday, May 12, 2025. Photo by Chris Kleponis/Pool/ABACAPRESS.COM

E

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo

E

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo

E

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo

E

Ghana approves vaccine for children against malaria

STORY: Ghana approves vaccine for children against malaria DATELINE: April 15, 2023 LENGTH: 00:03:49 LOCATION: Accra CATEGORY: HEALTH SHOTLIST: 1. STANDUP (English): JUSTICE ADOBOE, Xinhua reporter 2. various of Accra 3. various of Delese Darko, the chief executive officer of Ghana's Food and Drugs Authority 4. various of Ghana's Food and Drugs Authority 5. various of hospital (files) 6. SOUNDBITE 1 (English): DELESE DARKO, Chief executive officer of Ghana's FDA 7. SOUNDBITE 2 (English): SAMMY OHENE, Chairman of the governing board of Ghana's FDA 8. various of hospitals (files) STORYLINE: Ghana, one of the world's most serious malaria-stricken countries, approved on Thursday a new vaccine for children to protect them from the deadly disease. STANDUP (English): JUSTICE ADOBOE, Xinhua reporter "Malaria has been a major contributor to under-five mortality in Ghana. But the good news is that this phenomenon will soon be a thing of the past, as the Ghanaian food and drugs authority has given approval for th

E

U.S.-WASHINGTON, D.C.-HEARING-FDA-COMMISSIONER

(220428) -- WASHINGTON, April 28, 2022 (Xinhua) -- U.S. Food and Drug Administration Commissioner Robert Califf attends a hearing of U.S. Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, titled "A Review of the President's Fiscal Year 2023 Budget Request for the Food and Drug Administration" on Capitol Hill in Washington, D.C., the United States, on April 28, 2022. (Photo by Ting Shen/Xinhua)

E

U.S.-WASHINGTON, D.C.-HEARING-FDA-COMMISSIONER

(220428) -- WASHINGTON, April 28, 2022 (Xinhua) -- U.S. Food and Drug Administration Commissioner Robert Califf attends a hearing of U.S. Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, titled "A Review of the President's Fiscal Year 2023 Budget Request for the Food and Drug Administration" on Capitol Hill in Washington, D.C., the United States, on April 28, 2022. (Photo by Ting Shen/Xinhua)

E

U.S.-WASHINGTON, D.C.-HEARING-FDA-COMMISSIONER

(220428) -- WASHINGTON, April 28, 2022 (Xinhua) -- U.S. Food and Drug Administration Commissioner Robert Califf attends a hearing of U.S. Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, titled "A Review of the President's Fiscal Year 2023 Budget Request for the Food and Drug Administration" on Capitol Hill in Washington, D.C., the United States, on April 28, 2022. (Photo by Ting Shen/Xinhua)

E

U.S.-WASHINGTON, D.C.-HEARING-FDA-COMMISSIONER

(220428) -- WASHINGTON, April 28, 2022 (Xinhua) -- U.S. Food and Drug Administration Commissioner Robert Califf (Front) attends a hearing of U.S. Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, titled "A Review of the President's Fiscal Year 2023 Budget Request for the Food and Drug Administration" on Capitol Hill in Washington, D.C., the United States, on April 28, 2022. (Photo by Ting Shen/Xinhua)

E

U.S.-WASHINGTON, D.C.-HEARING-FDA-COMMISSIONER

(220428) -- WASHINGTON, April 28, 2022 (Xinhua) -- U.S. Food and Drug Administration Commissioner Robert Califf attends a hearing of U.S. Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, titled "A Review of the President's Fiscal Year 2023 Budget Request for the Food and Drug Administration" on Capitol Hill in Washington, D.C., the United States, on April 28, 2022. (Photo by Ting Shen/Xinhua)

E

U.S.-WASHINGTON, D.C.-HEARING-FDA-COMMISSIONER

(220428) -- WASHINGTON, April 28, 2022 (Xinhua) -- U.S. Food and Drug Administration Commissioner Robert Califf attends a hearing of U.S. Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, titled "A Review of the President's Fiscal Year 2023 Budget Request for the Food and Drug Administration" on Capitol Hill in Washington, D.C., the United States, on April 28, 2022. (Photo by Ting Shen/Xinhua)

E

U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

(220415) -- WASHINGTON, D.C., April 15, 2022 (Xinhua) -- A screenshot taken on April 14, 2022 from a video released by InspectIR Systems shows the InspectIR PNY-1000 COVID Testing Demo. The U.S. Food and Drug Administration (FDA) issued an emergency use authorization on Thursday for the country's first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor's offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage, according to the FDA. The results of the test will show in less than three minutes. The performance of the test, called InspectIR COVID-19 Breathalyzer, was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2 percent sensitivity and 99.3 percent specificity, according to the FDA.

E

U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

(220415) -- WASHINGTON, D.C., April 15, 2022 (Xinhua) -- A screenshot taken on April 14, 2022 from a video released by InspectIR Systems shows the InspectIR PNY-1000 COVID Testing Demo. The U.S. Food and Drug Administration (FDA) issued an emergency use authorization on Thursday for the country's first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor's offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage, according to the FDA. The results of the test will show in less than three minutes. The performance of the test, called InspectIR COVID-19 Breathalyzer, was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2 percent sensitivity and 99.3 percent specificity, according to the FDA.

E

U.S.-WASHINGTON, D.C.-COVID-19 TEST DEMO

(220415) -- WASHINGTON, D.C., April 15, 2022 (Xinhua) -- A screenshot taken on April 14, 2022 from a video released by InspectIR Systems shows the InspectIR PNY-1000 COVID Testing Demo. The U.S. Food and Drug Administration (FDA) issued an emergency use authorization on Thursday for the country's first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection. The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor's offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage, according to the FDA. The results of the test will show in less than three minutes. The performance of the test, called InspectIR COVID-19 Breathalyzer, was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2 percent sensitivity and 99.3 percent specificity, according to the FDA.

E

Moderna to request FDA's approval for vaccinating children aged under 6

STORY: Moderna to request FDA's approval for vaccinating children aged under 6 DATELINE: March 24, 2022 LENGTH: 00:01:24 LOCATION: Washington D.C. CATEGORY: HEALTH SHOTLIST: 1. various of American biotechnology company Moderna related footage STORYLINE: American biotechnology company Moderna said Wednesday it will request the U.S. Food and Drug Administration (FDA) to grant emergency use authorization for its COVID-19 vaccine for children aged under 6. The company will submit the request to the FDA, as well as the European Medicines Agency and other global regulators "in the coming weeks," said the company in a statement. The submission was based on tests of its COVID-19 vaccine, known as mRNA-1273, in children aged 6 months to under 2 years, and 2 years to under 6 years. The interim analysis showed a robust neutralizing antibody response in both age groups after a 25 microgram two-dose primary series of mRNA-1273 along with a favorable safety profile, according to the company. In the study, vaccine ef

E

Pfizer, Moderna seek FDA's authorization for second COVID-19 booster shots

STORY: Pfizer, Moderna seek FDA's authorization for second COVID-19 booster shots DATELINE: March 19, 2022 LENGTH: 00:02:36 LOCATION: Washington D.C. CATEGORY: HEALTH SHOTLIST: 1. various of the vaccine production line STORYLINE: American biotechnology company Moderna submitted a request to the U.S. Food and Drug Administration (FDA) on Thursday for emergency use authorization (EUA) on a fourth dose of its COVID-19 vaccine for adults 18 years of age and older, who already received a booster dose of any approved or authorized shot. The request to include adults over 18 years of age was made to provide flexibility for the U.S. Centers for Disease Control and Prevention and healthcare providers to "determine the appropriate use of an additional booster dose," including for those at higher risk of COVID-19 due to age or comorbidities, said the company in a statement. Currently a booster dose of the Moderna COVID-19 vaccine at the 50 microgram dose level is authorized by the FDA for emergency use in the Unite

E

Philippines approves emergency use of Sinovac COVID-19 vaccine for children

STORY: Philippines approves emergency use of Sinovac COVID-19 vaccine for children DATELINE: March 14, 2022 LENGTH: 00:01:14 LOCATION: Manila CATEGORY: HEALTH SHOTLIST: 1. various of street views in Manila 2. footage of Chinese vaccine arriving at Philippine airport 3. various of Filipinos receiving COVID-19 jabs STORYLINE: The Philippines' Food and Drug Administration (FDA) has granted the emergency use authorization for China's Sinovac COVID-19 vaccine for children, Health Secretary Francisco Duque said on Monday. Duque said the government would soon administer the Sinovac COVID-19 vaccine, or the inactivated CoronaVac vaccine, to children aged six and above. "We are just looking at the operational details to implement this. But it will not take long," Duque added. CoronaVac is the second COVID-19 vaccine allowed to be administered to children in the Philippines. The FDA earlier granted emergency use of Pfizer vaccine for children. The Sinovac vaccine is also the first vaccine delivered in Manila as C

E

Covid Antiviral Pill Can Halve Risk Of Hospitalisation

Handout - An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease. US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for emergency use authorisation for the drug in the US in the next two weeks. Dr Anthony Fauci, chief medical adviser to US President Joe Biden, said the results were "very good news", but urged caution until the US Food and Drug Administration (FDA) had reviewed the data. Photo courtesy of Merck Sharp & Dohme Corp via ABACAPRESS.COM

E

Covid Antiviral Pill Can Halve Risk Of Hospitalisation

Handout - An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease. US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for emergency use authorisation for the drug in the US in the next two weeks. Dr Anthony Fauci, chief medical adviser to US President Joe Biden, said the results were "very good news", but urged caution until the US Food and Drug Administration (FDA) had reviewed the data. Photo courtesy of Merck Sharp & Dohme Corp via ABACAPRESS.COM

E

Covid Antiviral Pill Can Halve Risk Of Hospitalisation

Handout - An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease. US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for emergency use authorisation for the drug in the US in the next two weeks. Dr Anthony Fauci, chief medical adviser to US President Joe Biden, said the results were "very good news", but urged caution until the US Food and Drug Administration (FDA) had reviewed the data. Photo courtesy of Merck Sharp & Dohme Corp via ABACAPRESS.COM

E

President Joe Biden Delivers Remarks and Receives a COVID-19 Booster Shot

President Joe Biden delivers remarks and receives a COVID-19 booster shot in line with the CDC's and FDA's recommendations in the South Court Auditorium of the Eisenhower Executive Office Building September 27, 2021 in Washington DC. Photo by Ken Cedeno/Pool/ABACAPRESS.COM

E

Fauci and Walensky Testify on Covid at Senate committee Hearing

Janet Woodcock, acting commissioner of the US Food and Drug Administration (FDA), speaks during a Senate Health, Education, Labor, and Pensions Committee hearing at the Dirksen Senate Office Building in Washington, DC, USA, on Tuesday, July 20, 2021. Photo by Stefani Reynolds/Pool/ABACAPRESS.COM

E

Fauci and Walensky Testify on Covid at Senate committee Hearing

Janet Woodcock, acting commissioner of the U.S. Food and Drug Administration (FDA), listens during a Senate Health, Education, Labor, and Pensions Committee hearing at the Dirksen Senate Office Building in Washington, DC, USA, on Tuesday, July 20, 2021. Photo by Stefani Reynolds/Pool/ABACAPRESS.COM

E

Fauci and Walensky Testify on Covid at Senate committee Hearing

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, left, and Janet Woodcock, acting commissioner of the U.S. Food and Drug Administration (FDA), listen during a Senate Health, Education, Labor, and Pensions Committee hearing at the Dirksen Senate Office Building in Washington, DC, USA, on Tuesday, July 20, 2021. Photo by Stefani Reynolds/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Covid-19 Hearing - Washington

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, May 11, 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Anthony Fauci (L), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); Peter Marks (C-R), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), speak to prepare Democratic Senator from Washington Patty Murray (C-L) prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Anthony Fauci (L), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); Peter Marks (C-R), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), speak to prepare Democratic Senator from Washington Patty Murray (C-L) prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; David Kessler (C-L), Chief Science Officer for COVID Response at the Department of Health and Human Services (HHS); Anthony Fauci (C-R), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prepare to testify before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; David Kessler (C-L), Chief Science Officer for COVID Response at the Department of Health and Human Services (HHS); Anthony Fauci (C-R), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prepare to testify before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM